Paraneoplastic optic neuropathy associated with papillary renal cell carcinoma

Srikantha, Nishanthan; Goverdhan, Srini; Evans, Anthony

doi:10.1136/bjo.2009.161455

Cited by 8 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32,55,160,170,189,241,259,275,279 Other associations include Bcell lymphoma, 54,197,234 pancreatic glucagonoma, 154 neuroblastoma, 133,254 uterine sarcoma, 272 breast, 18,228 prostate, 44 nasopharyngeal, 105 bronchial, 220 papillary thyroid, 55,151 nonsmall cell lung, 21,192 and renal cell carcinomas. 55,108,268 Patients classically present with subacute, bilateral, painless vision loss that progresses over days to weeks. The optic nerve head may appear normal, edematous, or atrophic at the time of initial examination.…”

Section: Managementmentioning

confidence: 99%

Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: Evaluation and management

Rahimy¹,

Sarraf

2013

Survey of Ophthalmology

165

148

View full text Add to dashboard Cite

Section: Managementmentioning

confidence: 99%

Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: Evaluation and management

Rahimy¹,

Sarraf

2013

Survey of Ophthalmology

165

148

View full text Add to dashboard Cite

“…Paraneoplastic manifestations, with constitutional signs and symptoms (fever, cachexia, and weight loss), hypertension and/or metabolic anomalies (hypercalcemia, polycythemia, amyloidosis, hepatic dysfunction, and Cushing's syndrome) can also be present as in other RCCs [76]. For instance, new-onset proteinuria and various neuropathies have been documented specifically in pRCC cases [80][81][82][83].…”

Section: Gradementioning

confidence: 99%

Long Non-Coding RNAs as Novel Biomarkers in the Clinical Management of Papillary Renal Cell Carcinoma Patients: A Promise or a Pledge?

Trevisani

Floris

Vago

et al. 2022

Cells

View full text Add to dashboard Cite

Papillary renal cell carcinoma (pRCC) represents the second most common subtype of renal cell carcinoma, following clear cell carcinoma and accounting for 10–15% of cases. For around 20 years, pRCCs have been classified according to their mere histopathologic appearance, unsupported by genetic and molecular evidence, with an unmet need for clinically relevant classification. Moreover, patients with non-clear cell renal cell carcinomas have been seldom included in large clinical trials; therefore, the therapeutic landscape is less defined than in the clear cell subtype. However, in the last decades, the evolving comprehension of pRCC molecular features has led to a growing use of target therapy and to better oncological outcomes. Nonetheless, a reliable molecular biomarker able to detect the aggressiveness of pRCC is not yet available in clinical practice. As a result, the pRCC correct prognosis remains cumbersome, and new biomarkers able to stratify patients upon risk of recurrence are strongly needed. Non-coding RNAs (ncRNAs) are functional elements which play critical roles in gene expression, at the epigenetic, transcriptional, and post-transcriptional levels. In the last decade, ncRNAs have gained importance as possible biomarkers for several types of diseases, especially in the cancer universe. In this review, we analyzed the role of long non-coding RNAs (lncRNAs) in the prognosis of pRCC, with a particular focus on their networking. In fact, in the competing endogenous RNA hypothesis, lncRNAs can bind miRNAs, resulting in the modulation of the mRNA levels targeted by the sponged miRNA, leading to additional regulation of the target gene expression and increasing complexity in the biological processes.

show abstract

“…PON is rare, and the signs, symptoms, and radiographic workup is variable. Most cases are related to an underlying small-cell lung carcinoma, although many other case reports have been described in the literature associated with other malignancy including hemopoietic cancers (48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66). Visual acuity can be reduced by any degree, and there are other signs of optic nerve dysfunction such as color vision defects and visual field defects (67).…”

Section: Ponmentioning

confidence: 99%

Neuro-ophthalmic manifestations of cancer: a narrative review

Janetos¹,

Volpe²,

Simon³

2022

Chin Clin Oncol

View full text Add to dashboard Cite

Background and Objective: Neuro-ophthalmic manifestations of cancer are vast and early recognition of a serious ocular condition due to either cancer or its therapy is important for both vision preservation as well as providing valuable treatment and prognostic information regarding the underlying malignancy. This review focuses on direct and indirect effects of cancer on the eye and its adnexa, hematologic malignancy, complications of traditional and novel oncologic therapies, and paraneoplastic syndromes as they relate to the eye as these disorders can lead to potentially devastating or irreversible vision loss.Methods: PubMed was searched primarily for the following topics: optic nerve infiltration, primary vitreoretinal lymphoma (PVRL), ocular paraneoplastic disorders, and ophthalmic complications of cancer therapeutics. Literature was selected based on historical significance and landmark studies (e.g., Cross et al.series of paraneoplastic optic neuritis patients; Chan's textbook on primary intraocular lymphoma) as well as publications published after 2000. References from select studies were additionally included. Given the sparsity of literature on many subjects, most publications were included during this time frame in our review.

show abstract

Paraneoplastic optic neuropathy associated with papillary renal cell carcinoma

Cited by 8 publications

References 11 publications

Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: Evaluation and management

Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: Evaluation and management

Long Non-Coding RNAs as Novel Biomarkers in the Clinical Management of Papillary Renal Cell Carcinoma Patients: A Promise or a Pledge?

Neuro-ophthalmic manifestations of cancer: a narrative review

Contact Info

Product

Resources

About